High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
about
Stem cell transplantation for neuroblastomaNeuroblastoma: issues in transplantationActivating mutations in ALK provide a therapeutic target in neuroblastoma.Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virusAcquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomesExpression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyRecent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesEfficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005).Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma.Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma.Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.Plasticity and maintenance of hematopoietic stem cells during development.Advances in Risk Classification and Treatment Strategies for Neuroblastoma.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionThe role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma.Primary intrathoracic malignant neurogenic tumor: report of three cases and comparison with benign neurogenic tumors resected at our institution.Hematologic recovery after tandem high-dose chemotherapy and autologous stem cell transplantation in children with high-risk solid tumors.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue SarcomasManagement and outcome of stage 3 neuroblastoma.Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.Retrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastomaNeuroblastoma originating from extra-abdominal sites: association with favorable clinical and biological features.High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma.Optimal time to start peripheral blood stem cell collection in children with high-risk solid tumors.
P2860
Q24629221-B6B02EBD-270A-4860-83E0-AD030489536AQ27008197-DF0B7714-7546-4801-B84C-2F80C882080EQ27851452-E9FA68A3-527B-43E8-9F09-40E0E38AB95FQ28474594-0E129A8D-6A20-43F7-B409-0FC68BA25C9FQ30657233-F2FD3805-9A51-46F9-B62F-972CC84CD5AFQ33349703-39FCFA9B-6AC4-4933-8C14-6DE286FC6B5BQ33691441-F0E0B05C-D90E-4956-922D-2C014432EDB4Q33730375-2F7DABD3-7256-40AB-B485-B5008A27A9DEQ33807214-801B67CC-FA58-43B0-99ED-43A5A9ED3E9DQ33908476-CF5DDD68-23D7-44F7-A961-87B891E37496Q33916362-26081B86-3D9F-430A-B413-482C0CF6D843Q33924534-68F0A227-CA5D-4F76-AD8B-7CD0A67C80D8Q34200900-4B3F375B-D781-4CDC-999C-F13E39160389Q34351080-14921245-ED6A-497B-9813-77B72F4E2AB6Q34549193-D1A9064F-CE96-4666-BE43-92DB515FFB6CQ34660375-BC002D34-31A0-4003-AAC1-4F503D2C3152Q34667915-86F44B95-35BF-4F03-9CB9-0BE7BD5FD668Q34703990-1B68AC15-F085-4E31-8CE5-54C78AF037E2Q34785880-4F17BF41-BABF-45EF-9A4E-BFFE8288AFD7Q34891827-6D65C336-7440-4121-9138-E217727FF2FFQ35077703-AD1CD157-4525-4543-A053-1DE41DB0071AQ35798960-FA4A90FB-50B8-4325-ABA5-0A9C004EF746Q35804722-70A80A86-3632-4603-946A-56FBDEFED805Q36053801-733C03F1-D821-4A76-9482-63907CC7A6B9Q36212437-294C30E7-C821-4849-B175-64759DE4DD72Q36411061-073086BA-2308-4C79-8CDD-8F59180099C2Q36564034-09377B77-3A5C-422C-BD28-ABE1A41C1543Q36589477-C3E9EB51-F023-45A1-989E-C732C7BAEA0CQ36782374-AB9B494F-6677-4B88-80EA-EB9F3E6A2844Q36800194-3A1566DD-DC6B-4B73-8781-642D94B01D44Q36867863-F03CA0C2-CE44-4B68-B7BF-876A1594CEFAQ36910335-37D423FA-4831-4387-BDDA-4761EEC3EECDQ36989758-69892A57-C0C1-4471-9250-A990D0B14897Q37056086-36FB0AE9-3ACB-4D42-8A1E-14E4224283C6Q37144023-78B1A062-6CBE-4CD5-9621-B9454904F0ECQ37222520-7048EAC1-1974-45C6-8E61-968729FD840BQ37232057-68946063-9065-48AE-87F0-152E451CFA37Q37284671-560D5C4E-30FF-424C-8780-AB81B1494867Q37451551-A8D6A711-1702-491B-8AD8-C230E00D928BQ37473582-1F40E111-1C35-46AB-94CE-A7CAC47AC5D5
P2860
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High-risk neuroblastoma treate ...... on: long-term survival update.
@ast
High-risk neuroblastoma treate ...... on: long-term survival update.
@en
High-risk neuroblastoma treate ...... on: long-term survival update.
@nl
type
label
High-risk neuroblastoma treate ...... on: long-term survival update.
@ast
High-risk neuroblastoma treate ...... on: long-term survival update.
@en
High-risk neuroblastoma treate ...... on: long-term survival update.
@nl
prefLabel
High-risk neuroblastoma treate ...... on: long-term survival update.
@ast
High-risk neuroblastoma treate ...... on: long-term survival update.
@en
High-risk neuroblastoma treate ...... on: long-term survival update.
@nl
P2093
P356
P1476
High-risk neuroblastoma treate ...... on: long-term survival update.
@en
P2093
Cheryl Medeiros-Nancarrow
Donna Neuberg
Karen Marcus
Lisa Diller
Michael Pulsipher
Rani E George
Robert C Shamberger
Stephan A Grupp
P304
P356
10.1200/JCO.2006.05.6986
P407
P577
2006-06-01T00:00:00Z